Scientists have uncovered 52 new genetic changes linked to osteoarthritis, doubling the number of genetic regions found to be associated with the disabling condition, potentially paving the way for the development of disease-modifying therapies.
News
It’s not too late to start your application and beat the January 31st deadline
With entries already surpassing the overall for last year, this year’s 20th anniversary edition of the competition is shaping up to be our largest one yet – so join your fellow peers and enter now!
MAGI Boston conference 2019 – benefits available for clinical researcher of the year finalists
MAGI and PharmaTimes have teamed up to offer Clinical Researcher of the Year – The Americas finalists discounts at the MAGI Boston conference in May.
Canopy Growth to open UK medicinal cannabis branch
US based Canopy Growth has declared its intent to enter the UK market, by unveiling new pharmaceutical company Spectrum Biomedical UK – a joint venture between Canopy Growth and Beckley Canopy.
NAO report highlights NHS financial deficit
NHS trusts and foundation trusts have booked a combined deficit of £991 million for 2017/18, according to the National Audit Office’s latest report on NHS financial sustainability.
Trivalent gets UK green light for flu in over 65s
UK marketing authorisation has been granted for Sanofi Pasteur’s Trivalent Influenza Vaccine High Dose for people 65 years and older.
Imbruvica fails Phase III pancreatic cancer trial
A late-stage trial testing AbbVie’s Imbruvica in combination with chemotherapy for metastatic pancreatic adenocarcinoma (cancer) has failed to meet its primary endpoint.
Researchers identify new genes linked to age-related macular degeneration
Fight for Sight has announced a breakthrough in identifying new genes in age-related macular degeneration, the leading cause of blindness.
New funding for neurodegenerative research in Scotland
The University of St Andrews is administering a new funding pool for researchers working on neurodegenerative conditions.
NICE OK for Braftovi skin cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Braftovi and Mektovi combination as an option for some people with melanoma.
Janssen to use Apple watch for AFib
Johnson & Johnson’s Janssen has announced a research study using the Apple watch to help improve atrial fibrillation (AFib) outcomes, including stroke prevention, intending to to collaborate with Apple to assess the impact of the wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes.
Positive results for UB-311 Alzheimer’s vaccine
United Neuroscience has announced a positive top-line results from the Phase IIa clinical study of UB-311 vaccine in patients with Alzheimer’s disease.
Venetoclax gets NICE approval for chronic lymphocytic leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto to benefit thousands of adults with chronic lymphocytic leukaemia.
Novartis and Uni of Oxford to join forces and use AI for diseases and drug development
Novartis and the University of Oxford’s Big Data Institute have announced that they are to establish a five-year research alliance using artificial intelligence to understand complex diseases and improve drug development.
Immune cell clues offer hope to hypertension patients
Researchers led by the University of Edinburgh have pinpointed cells in the immune system that could be key to tackling high blood pressure.
